Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adriamycin + cyclophosphamide + dexamethasone + quinine + verapamil + vincristine
- Development stage
- Preclinical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of six drugs: - Adriamycin (doxorubicin): an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and generating free radicals, leading to cytotoxicity. - Cyclophosphamide: an alkylating agent that crosslinks DNA strands, preventing cell division. - Dexamethasone: a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects; used here for its lympholytic activity. - Vincristine: a vinca alkaloid that inhibits microtubule formation in mitosis, arresting cell division. - Verapamil: a calcium channel blocker used as a chemosensitizer to inhibit P-glycoprotein-mediated drug efflux (multidrug resistance). - Quinine: an antimalarial also used as a chemosensitizer to inhibit drug resistance mechanisms. This specific combination is not standard but has been studied in patients with breast cancer who failed conventional CVAD therapy. The addition of verapamil and quinine aims to overcome multidrug resistance by sensitizing tumor cells to chemotherapy. The regimen has shown some additional clinical responses in refractory cases[1].
- Other names
- CVAD plus verapamil and quinine
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)ABCB1 (P-glycoprotein)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on adriamycin + cyclophosphamide + dexamethasone + quinine + verapamil + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adriamycin + cyclophosphamide + dexamethasone + quinine + verapamil + vincristine.